SOURCE: Conformia

August 18, 2008 07:00 ET

Conformia Integrates SOA-Based Product/Process Lifecycle Management Into IBM Platform for Pharmaceutical Development

IBM Platform Now Includes SOA-Validated Development and Scale Up Management System Software for a More Robust End-to-End Solution

SUNNYVALE, CA--(Marketwire - August 18, 2008) - Conformia, the market leader and innovator of enterprise solutions for product/process lifecycle management (PPLM) for regulated process manufacturing industries, today announced it has integrated its solution into the IBM platform to provide an end-to-end solution for drug development to the pharmaceutical industry. The solution incorporates service oriented architecture (SOA) capabilities that have been validated by IBM. Conformia's SOA approach enables other applications running on the IBM stack and infrastructure to exchange crucial pharmaceutical data with Conformia's products. Furthermore, data from non-IBM products can now be integrated into Conformia and IBM product stacks creating the first commercial off-the-shelf, integrated information environment solution for pharmaceutical and biotech drug development.

Conformia fulfilled the IBM PartnerWorld® SOA validation criteria for their solution in December, and is working with IBM to deliver both the strategic business transformation and the commercial off-the-shelf software systems that pharmaceutical developers need to support sustainability of their transformation strategies. With the Conformia SOA platform, drug developers will be able to reduce development lifecycles, increase operational visibility and traceability, improve product quality, and decrease the costs associated with regulatory non-compliance -- all while achieving major gains in data integration.

Working together, Conformia and IBM provide the pharmaceutical industry with enterprise software on a reliable, robust technology stack that links data around early experiments, pilot plant scale-up as well as full-scale manufacturing, along with proven business processes and deployment capabilities.

"As one of the most heavily regulated and complex industries, the pharmaceutical sector presents a myriad of unique challenges to organizations during their product-development lifecycles, and, until now, few have stepped forward to help," said Dan Pelino, general manager, IBM Global Healthcare and Life Sciences. "Together, Conformia and IBM are helping to deliver a clear path for these organizations to follow -- one that allows them to create an integrated data and information environment resulting in more effective knowledge-management programs, which they are now demanding."

"Combining our deep pharmaceutical and biotech expertise with IBM's strength in pharmaceutical industry business transformation delivers a groundbreaking new approach to help companies implement new development strategies such as the Quality by Design Paradigm or the ICH Quality Vision. This helps solve some of the biggest issues in drug development," said Anjali Kataria, founder and chief marketing officer of Conformia. "Our work with IBM both validates and strengthens our continued dedication to making product development more efficient so scientific leadership can do more with the same resources."

About Conformia

Conformia Software is the leading provider of product/process lifecycle management (PPLM) software solutions to regulated process industries including life sciences. Conformia solutions enable faster time to market, reduced costs and decreased risk. As a company, Conformia remains a thought leader in addressing the most pressing issues facing pharmaceutical development teams across the globe such as implementation of ICH Quality Vision. For more information, go to: www.conformia.com.

Contact Information